Retatrutide vs Exenatide
An investigational GIP/GLP-1/glucagon triple receptor agonist. A GLP-1 receptor agonist derived from Gila monster venom (exendin-4). Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Retatrutide | Exenatide | |
|---|---|---|
| Also known as | — | Byetta, Bydureon |
| Type | Analog | Analog |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GIP/GLP-1/glucagon triple agonist (acylated peptide) | GLP-1 receptor agonist (exendin-4, 39 aa) |
| Receptor | GIP + GLP-1 + glucagon receptors | GLP-1 receptor (GLP-1R) |
| Molecular weight | ≈4,900 Da | ~4,186.6 Da |
| Half-life | ||
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Retatrutide and Exenatide?
- Retatrutide is an engineered analog based on Glucagon-like peptide-1; Exenatide is an engineered analog based on Glucagon-like peptide-1. Retatrutide signals at GIP + GLP-1 + glucagon receptors; Exenatide signals at GLP-1 receptor (GLP-1R).
- How do the half-lives of Retatrutide and Exenatide compare?
- The reported circulating half-life of Retatrutide is ~6 days; Exenatide is ~2.4 h (immediate-release). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Exenatide vs Retatrutide. Or open the interactive comparison tool to add more molecules.